The barrier functions of crude cervical mucus plugs against HIV-1 infection in the context of cell-free and cell-to-cell transmission.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
23
6
2021
medline:
14
10
2021
entrez:
22
6
2021
Statut:
ppublish
Résumé
The cervical mucus plugs are enriched with proteins of known immunological functions. We aimed to characterize the anti-HIV-1 activity of the cervical mucus plugs against a panel of different HIV-1 strains in the contexts of cell-free and cell-associated virus. A cohort of consenting HIV-1-negative and HIV-1-positive pregnant women in labour was recruited from Mthatha General Hospital in the Eastern Cape province of South Africa, from whom the cervical mucus plugs were collected in 6 M guanidinium chloride with protease inhibitors and transported to our laboratories at -80 °C. Samples were centrifuged to remove insoluble material and dialysed before freeze--drying and subjecting them to the cell viability assays. The antiviral activities of the samples were studied using luminometric reporter assays and flow cytometry. Time-of-addition and BlaM-Vpr virus-cell fusion assays were used to pin-point the antiviral mechanisms of the cervical mucus plugs, before proteomic profiling using liquid chromatography-tandem mass spectrometry. The proteinaceous fraction of the cervical mucus plugs exhibited anti-HIV-1 activity with inter-individual variations and some degree of specificity among different HIV-1 strains. Cell-associated HIV-1 was less susceptible to inhibition by the potent samples whenever compared with the cell-free HIV-1. The samples with high antiviral potency exhibited a distinct proteomic profile when compared with the less potent samples. The crude cervical mucus plugs exhibit anti-HIV-1 activity, which is defined by a specific proteomic profile.
Identifiants
pubmed: 34155151
doi: 10.1097/QAD.0000000000003003
pii: 00002030-202111010-00005
pmc: PMC8505157
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2105-2117Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Bansil R, Turner BS. Mucin structure, aggregation, physiological functions and biomedical applications . Curr Opin Colloid Interface Sci 2006; 11:164–170.
Fahy JV, Dickey BF. Airway mucus function and dysfunction . N Engl J Med 2010; 363:2233–2247.
Corfield AP. Mucins: a biologically relevant glycan barrier in mucosal protection . Biochim Biophys Acta 2015; 1850:236–252.
Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of human immunodeficiency virus type 1 in an inhibition assay . Virol J 2006; 3:99.
Habte HH, Kotwal GJ, Lotz ZE, Tyler MG, Abrahams M, Rodriques J, et al. Antiviral activity of purified human breast milk mucin . Neonatology 2007; 92:96–104.
Viergiver E, Pommerenke WT. Measurement of the cylcic variations in the quantity of cervical mucus and its correlation wth basal temperature . Am J Obstet Gynecol 1944; 48:321–328.
Wolf DP, Blasco L, Khan MA, Litt M. Human cervical mucus. IV. Viscoelasticity and sperm penetrability during the ovulatory menstrual cycle . Fertil Steril 1978; 30:163–169.
Lee DC, Hassan SS, Romero R, Tarca AL, Bhatti G, Gervasi MT, et al. Protein profiling underscores immunological functions of uterine cervical mucus plug in human pregnancy . J Proteomics 2011; 74:817–828.
Hein M, Petersen AC, Helmig RB, Uldbjerg N, Reinholdt J. Immunoglobulin levels and phagocytes in the cervical mucus plug at term of pregnancy . Acta Obstet Gynecol Scand 2005; 84:734–742.
Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of mucus . Adv Drug Delivery Rev 2009; 61:86–100.
Becher N, Adams Waldorf K, Hein M, Uldbjerg N. The cervical mucus plug: structured review of the literature . Acta Obstet Gynecol Scand 2009; 88:502–513.
Freitas AC, Chaban B, Bocking A, Rocco M, Yang S, Hill JE, et al. The vaginal microbiome of pregnant women is less rich and diverse, with lower prevalence of Mollicutes, compared to nonpregnant women . Sci Rep 2017; 7:9212.
Gipson IK, Ho SB, Spurr-Michaud SJ, Tisdale AS, Zhan Q, Torlakovic E, et al. Mucin genes expressed by human female reproductive tract epithelia . Biol Reprod 1997; 56:999–1011.
Andersch-Bjorkman Y, Thomsson KA, Holmen Larsson JM, Ekerhovd E, Hansson GC. Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle . Mol Cell Proteomics 2007; 6:708–716.
Gipson IK, Spurr-Michaud S, Tisdale A, Menon BB. Comparison of the transmembrane mucins MUC1 and MUC16 in epithelial barrier function . PLoS One 2014; 9:e100393.
Hanson RL, Hollingsworth MA. Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (downstream effects on signaling) . Biomolecules 2016; 6:3.
Gipson IK, Spurr-Michaud S, Moccia R, Zhan Q, Toribara N, Ho SB, et al. MUC4 and MUC5B transcripts are the prevalent mucin messenger ribonucleic acids of the human endocervix . Biol Reprod 1999; 60:58–64.
Gipson IK, Moccia R, Spurr-Michaud S, Argueso P, Gargiulo AR, Hill JA 3rd, et al. The Amount of MUC5B mucin in cervical mucus peaks at midcycle . J Clin Endocrinol Metab 2001; 86:594–600.
Hein M, Valore EV, Helmig RB, Uldbjerg N, Ganz T. Antimicrobial factors in the cervical mucus plug . Am J Obstet Gynecol 2002; 187:137–144.
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects . JAMA 2013; 310:2191–2194.
Habte HH, de Beer C, Lotz ZE, Tyler MG, Schoeman L, Kahn D, et al. The inhibition of the human immunodeficiency virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay . Virol J 2008; 5:59.
Carlstedt I, Lindgren H, Sheehan JK, Ulmsten U, Wingerup L. Isolation and characterization of human cervical-mucus glycoproteins . Biochem J 1983; 211:13–22.
Chirwa N, Mall A, Tyler M, Kavin B, Goldberg P, Krige JE, et al. Biochemical and immunohistochemical characterisation of mucins in 8 cases of colonic disease--a pilot study . South Afr J Surg 2007; 45:18–23.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature 1970; 227:680–685.
Lodermeyer V, Suhr K, Schrott N, Kolbe C, Sturzel CM, Krnavek D, et al. 90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1 . Retrovirology 2013; 10:111.
Stansell E, Desrosiers RC. Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages . J Virol 2010; 84:8998–9009.
Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Krausslich HG, et al. Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression . Retrovirology 2007; 4:53.
Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes . Nat Biotechnol 2002; 20:1151–1154.
Xu S, Ducroux A, Ponnurangam A, Vieyres G, Franz S, Musken M, et al. cGAS-mediated innate immunity spreads intercellularly through HIV-1 Env-induced membrane fusion sites . Cell Host Microbe 2016; 20:443–457.
Jochim N, Gerhard R, Just I, Pich A. Impact of clostridial glucosylating toxins on the proteome of colonic cells determined by isotope-coded protein labeling and LC-MALDI . Proteome Sci 2011; 9:48.
Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification . Nat Biotechnol 2008; 26:1367–1372.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets . Nucleic Acids Res 2019; 47 (D1):D607–d613.
Shimada K, Hayano M, Pagano NC, Stockwell BR. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity . Cell Chem Biol 2016; 23:225–235.
Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody . Nature 2020; 583:290–295.
Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies . PLoS Pathogens 2012; 8:e1002634.
Agosto LM, Herring MB, Mothes W, Henderson AJ. HIV-1-infected CD4+ T cells facilitate latent infection of resting CD4+ T cells through cell-cell contact . Cell Rep 2018; 24:2088–2100.
Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein . Nature 2011; 474:658–661.
Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies . PLoS One 2010; 5:e11366.
Anderson BL, Ghosh M, Raker C, Fahey J, Song Y, Rouse DJ, et al. In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women . Am J Obstet Gynecol 2012; 207:65.e1–65.e10.
Nunn KL, Wang YY, Harit D, Humphrys MS, Ma B, Cone R, et al. Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with lactobacillus crispatus-dominant microbiota . mBio 2015; 6:e01084–01015.
Tyssen D, Wang YY, Hayward JA, Agius PA, DeLong K, Aldunate M, et al. Anti-HIV-1 activity of lactic acid in human cervicovaginal fluid . mSphere 2018; 3:4.
Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery . Int J Pharm 2017; 532:555–572.
Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the ’gatekeeper’ problem resolved? . Nat Rev Microbiol 2006; 4:312–317.
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection . Science 1993; 261:1179–1181.
van’t Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission . J Clin Invest 1994; 94:2060–2067.
Becher N, Hein M, Danielsen CC, Uldbjerg N. Matrix metalloproteinases in the cervical mucus plug in relation to gestational age, plug compartment, and preterm labor . Reprod Biol Endocrinol 2010; 8:113.
Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus . J Virol 2000; 74:1961–1972.
Gundavarapu S, Mishra NC, Singh SP, Langley RJ, Saeed AI, Feghali-Bostwick CA, et al. HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/alpha7-nicotinic acetylcholine receptors . PLoS One 2013; 8:e77160.
Habte HH, de Beer C, Lotz ZE, Tyler MG, Kahn D, Mall AS. Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay . Neonatology 2008; 93:162–170.
Aboud L, Ball TB, Tjernlund A, Burgener A. The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV . Am J Reprod Immunol 2014; 71:12–23.
Soto PC, Karris MY, Spina CA, Richman DD, Varki A. Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells . J Mol Med (Berl) 2013; 91:261–270.
Sato K, Aoki J, Misawa N, Daikoku E, Sano K, Tanaka Y, et al. Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins . J Virol 2008; 82:1021–1033.
Moore T, Dveksler GS. Pregnancy-specific glycoproteins: complex gene families regulating maternal-fetal interactions . Int J Dev Biol 2014; 58 (2–4):273–280.
Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies . BMC Pregnancy Childbirth 2015; 15:246.
Hackeng TM, van ’t Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa . J Biol Chem 1994; 269:21051–21058.
Rasmussen LD, Dybdal M, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study . HIV medicine 2011; 12:202–210.
Olson JJ, Schwab PE, Jackson J, Lange JK, Bedair HS, Abdeen A. HIV-positive patients are at increased risk of venous thromboembolism after total joint replacement . J Am Acad Orthop Surg 2020; 29:479–485.
Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism . Am J Med Sci 2008; 336:402–406.
Osei Kuffour E, Konig R, Haussinger D, Schulz WA, Munk C. ISG15 deficiency enhances HIV-1 infection by accumulating misfolded p53 . mBio 2019; 10:4.
Brown C, Morham SG, Walsh D, Naghavi MH. Focal adhesion proteins talin-1 and vinculin negatively affect paxillin phosphorylation and limit retroviral infection . J Mol Biol 2011; 410:761–777.
Angin M, Volant S, Passaes C, Lecuroux C, Monceaux V, Dillies M-A, et al. Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection . Nat Metab 2019; 1:704–716.
Ventoso I, Blanco R, Perales C, Carrasco L. HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation . Proc Natl Acad Sci U S A 2001; 98:12966–12971.